TrialDiabetes care2023

Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.

Maciej T Małecki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.